Biotech | February 25, 2022
Biohaven licenses Taldefgrobep Alfa from Bristol Myers Squibb
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
Circular revenues already at 16% of sales, driven by healthcare informatics and services to enhance medical equipment uptime and utilization, system and software upgrades for enhanced functionality and extended lifetime and reusing refurbished parts and systems
Methodology developed by QIMR Berghofer researchers utilizing the Agilent Cary 630 FTIR
The Genome Valley region has played a pivotal role in fostering the life science industry and the state government has always supported its growth
The recently released WHO guideline on hypertension treatment (2021), recommends that patients with stable blood pressure can be asked to visit clinics at 3-6 month intervals as an important strategy to improve hypertension control
Cataract is the most common cause of blindness in India, and that diabetes is to be blamed for the massive number of damaged eyes
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
New expanded indication provides patients suffering from earlier stages of heart failure access to the CardioMEMS HF System, a small implantable sensor that can flag early warning signs of worsening heart failure
AIIA partners with Startup India with the aim to identify and support innovations and start-ups working in the Ayush sector
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
Subscribe To Our Newsletter & Stay Updated
